Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Katia, Boven"'
Autor:
Katia Boven, Richard E. Nettles, Kimberley Brown, Helen Pai, Magda Opsomer, Scott Chavers, Amy Purrington, Abdul Mehbob, Simon Vanveggel, Christiane Moecklinghoff, Johan Verspeelt, Dessislava Dimitrova, Donghan Luo
Publikováno v:
Drugs in R&D. 18:199-210
We evaluated cardiovascular disease (CVD) risk associated with darunavir treatment and examined the demographic/clinical characteristics of darunavir users based on data from Janssen-sponsored clinical trials, post-marketing pharmacovigilance databas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5ef2ded389cbf7cbf309c5ba0462c272
https://doi.org/10.1007/s40268-018-0238-8
https://doi.org/10.1007/s40268-018-0238-8
Autor:
Magda Opsomer, Simon Vanveggel, Amy Purrington, Richard E. Nettles, Kimberley Brown, Donghan Luo, Abdul Mehbob, Dessislava Dimitrova, Scott Chavers, Christiane Moecklinghoff, Helen Pai, Katia Boven, Johan Verspeelt
Publikováno v:
Drugs in R&D
Introduction We evaluated cardiovascular disease (CVD) risk associated with darunavir treatment and examined the demographic/clinical characteristics of darunavir users based on data from Janssen-sponsored clinical trials, post-marketing pharmacovigi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3a395d1d3082fc3c742bee5d25713c9
https://doi.org/10.1007/s40268-018-0243-y
https://doi.org/10.1007/s40268-018-0243-y
Autor:
Annemie Buelens, Herta Crauwels, Richard M. W. Hoetelmans, Rolf van Heeswijk, Katia Boven, Marita Stevens
Publikováno v:
The Journal of Clinical Pharmacology. 53:834-840
The objective of the study was to determine the impact of food and different meal types on the pharmacokinetics of rilpivirine, a nonnucleoside reverse transcriptase inhibitor. In this open-label, randomized, crossover study, healthy volunteers recei
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bd9c879ddb72153917b2383a9abe9e27
https://doi.org/10.1002/jcph.107
https://doi.org/10.1002/jcph.107
Autor:
Katia Boven, Simon Vanveggel, Gaston Picchio, Steven Nijs, Johan Vingerhoets, Laurence T. Rimsky, Veerle Van Eygen
Publikováno v:
Antiviral Therapy. 18:253-256
Background Rilpivirine (RPV), a non-nucleoside reverse transcriptase inhibitor (NNRTI), was approved for HIV-1 infected, antiretroviral treatment-naive adults based on data from two Phase III trials. In the screening population, the prevalence of 49
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fbe797e5636562001dd5681f0e93bd61
https://doi.org/10.3851/imp2358
https://doi.org/10.3851/imp2358
Autor:
Anthony Mills, Andrea Antinori, Echo, G Herrera, Katia Boven, Charles B. Hicks, Simon Vanveggel, Bonaventura Clotet, Jan Fourie, Thrive study groups, José Valdez Madruga, Marita Stevens
Publikováno v:
HIV Medicine. 14:391-400
Objectives The aim of the study was to compare the neuropsychiatric safety and tolerability of rilpivirine (TMC278) vs. efavirenz in a preplanned pooled analysis of data from the ECHO and THRIVE studies which compared the safety and efficacy of the t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7b03f21e762ff08c288a3bdbc52796fa
https://doi.org/10.1111/hiv.12012
https://doi.org/10.1111/hiv.12012
Autor:
Aimee, Wilkin, Anton L, Pozniak, Javier, Morales-Ramirez, Sergio H, Lupo, Mario, Santoscoy, Beatriz, Grinsztejn, Kiat, Ruxrungtham, Laurence T, Rimsky, Simon, Vanveggel, Katia, Boven, Melanie, Thompson
Publikováno v:
AIDS Research and Human Retroviruses. 28:437-446
TMC278-C204 (NCT00110305), a 96-week trial of the nonnucleoside reverse transcription inhibitor (NNRTI) rilpivirine (RPV, TMC278) in 368 HIV-1-infected, treatment-naive patients, was extended to investigate long-term safety and efficacy. Week 192 ana
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5f975ea759a796a04072eff99c8d348
https://doi.org/10.1089/aid.2011.0050
https://doi.org/10.1089/aid.2011.0050
Autor:
Katia Boven, L Mohapi, Keikawus Arastéh, P Kumar, William R. Short, J Gathe, J Gold, Herta Crauwels, S Hodder, Simon Vanveggel, J De Wet
Publikováno v:
HIV Medicine. 13:406-415
Objectives A week 48 efficacy and safety analysis with respect to gender and race was conducted using pooled data from the phase III, double-blind, double-dummy efficacy comparison in treatment-naive, HIV-infected subjects of TMC278 and efavirenz (EC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::227d681b0a783453bd8b3a8a751230f1
https://doi.org/10.1111/j.1468-1293.2012.00991.x
https://doi.org/10.1111/j.1468-1293.2012.00991.x
Autor:
Khuanchai Supparatpinyo, Herta Crauwels, Jean-Michel Molina, Simon Vanveggel, Anthony Mills, Laurence T. Rimsky, Adriano Lazzarin, Michael S. Saag, Sharon Walmsley, Pedro Cahn, Katia Boven, Beatriz Grinsztejn
Publikováno v:
The Lancet. 378:238-246
Summary Background Efavirenz with tenofovir-disoproxil-fumarate and emtricitabine is a preferred antiretroviral regimen for treatment-naive patients infected with HIV-1. Rilpivirine, a new non-nucleoside reverse transcriptase inhibitor, has shown sim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fc13bd78fe7a3bac16d4e8d194eaf9c8
https://doi.org/10.1016/s0140-6736(11)60936-7
https://doi.org/10.1016/s0140-6736(11)60936-7
Autor:
Anton L, Pozniak, Javier, Morales-Ramirez, Elly, Katabira, Dewald, Steyn, Sergio H, Lupo, Mario, Santoscoy, Beatriz, Grinsztejn, Kiat, Ruxrungtham, Laurence T, Rimsky, Simon, Vanveggel, Katia, Boven, Aimee, Wilkin
Publikováno v:
AIDS. 24:55-65
OBJECTIVE TMC278 is a next-generation nonnucleoside reverse transcriptase inhibitor highly active against wild-type and nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 in vitro. The week 96 analysis of TMC278-C204, a large dose-ranging
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2989a64522eb89ac292a997dcefbd39
https://doi.org/10.1097/qad.0b013e32833032ed
https://doi.org/10.1097/qad.0b013e32833032ed
Autor:
Scott Stryker, Nicole Casadevall, Adrian Thomas, Jerome Rossert, David A. Power, John Knight, Katia Boven, David M. Kemeny, Marc H. V. Van Regenmortel
Publikováno v:
Kidney International. 67(6):2346-2353
The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes.BackgroundThe incidence of pure red cell aplasia (PRCA) in chronic kidney disease patients treated with epoetins increased substantially in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b4b28a444e84e74ab96c5be459d910a